Mazdutide
KPV (Lysine-Proline-Valine) – Subcutaneous Injection only
Typical daily dose: 200–500 mcg once daily.
Range: Start at 200 mcg; titrate to 300–400 mcg; up to 500 mcg (some protocols 200–1,000 mcg).
Frequency: Once daily.
Reconstitution example (10 mg vial + 3 mL bacteriostatic water ≈ 3.33 mg/mL): – 200 mcg ≈ 6 units (0.06 mL) – 300 mcg ≈ 9 units (0.09 mL) – 400 mcg ≈ 12 units (0.12 mL) – 500 mcg ≈ 15 units (0.15 mL) on U-100 insulin syringe.
VIP (Vasoactive Intestinal Peptide) – Subcutaneous Injection only
Typical dose: 100–200 mcg per injection.
Range: Start 50–100 mcg; standard 100–200 mcg; up to 200–300 mcg (some protocols 400 mcg total daily divided).
Frequency: 1–2 times daily (or 5 times per week in some protocols).
Reconstitution example (5 mg vial + 5 mL bacteriostatic water = 1 mg/mL): – 100 mcg = 10 units (0.1 mL) – 200 mcg = 20 units (0.2 mL) on U-100 insulin syringe.
NAD+ – Subcutaneous Injection only
Typical dose: 50–100 mg per injection.
Range: Start 20–50 mg; standard 50–100 mg; up to 100–200 mg (some protocols reach 120 mg).
Frequency: 2–3 times per week (some start daily for 1 week then reduce to Mon–Fri).
Reconstitution / Concentration example (common 100 mg/mL solution): – 50 mg = 0.5 mL (50 units) – 100 mg = 1.0 mL (100 units) on U-100 insulin syringe.
Mazdutide – Subcutaneous Injection only
Typical maintenance dose: 4–9 mg once weekly (Phase 3 trials commonly use 4 mg, 6 mg, or 9 mg).
Range: 3–9 mg weekly (research explores up to 10–16 mg with extended titration).
Titration (slow escalation): – Weeks 1–4: 1.5–2 mg – Weeks 5–8: 3–4 mg – Weeks 9–12: 4.5–6 mg – Then 6–9 mg (or higher with further steps).
Frequency: Once weekly (same day each week).
Reconstitution example (10 mg vial + 3 mL bacteriostatic water ≈ 3.33 mg/mL): – 4 mg ≈ 120 units (1.2 mL) – 6 mg ≈ 180 units (1.8 mL) – 9 mg ≈ 270 units (2.7 mL) on U-100 insulin syringe.
Key Potential Benefits of Mazdutide
Robust and Dose-Dependent Weight Loss
Achieves substantial mean body weight reductions, with up to ~14–21% loss at higher doses (e.g., 6–16 mg) over 20–48 weeks in adults with overweight/obesity, often with continued loss and high responder rates (e.g., 67–75% achieving ≥15% loss at peak doses in some cohorts).
In Phase 3 trials (e.g., GLORY-1), 6 mg dosing led to ~14% weight loss at 48 weeks versus minimal change with placebo, with many participants reaching ≥10% or ≥15% thresholds.
Provides progressive fat mass reduction and waist circumference decreases (up to 10–17% in studies), supporting improved body composition and contouring without requiring lifestyle changes alone.
Superior Glycemic Control and Type 2 Diabetes Management
Delivers meaningful HbA1c reductions (up to ~2.03% from baseline in head-to-head trials), frequently outperforming comparators like semaglutide (e.g., -2.03% vs -1.84%) or dulaglutide.
In DREAMS-3 (head-to-head vs semaglutide), nearly half of participants (48%) achieved the composite of HbA1c <7.0% plus ≥10% weight loss, compared to 21% on semaglutide.
Improves fasting glucose, insulin sensitivity, and overall glucose regulation, with high rates of reaching HbA1c targets (<7.0% or ≤6.5%) when used in early-stage T2D with or without background metformin.
Enhanced Satiety, Appetite Suppression, and Energy Balance
GLP-1 receptor activation promotes strong feelings of fullness, reduces hunger signals, delays gastric emptying, and curbs cravings through central and peripheral pathways.
Glucagon receptor activation increases energy expenditure and fat oxidation, complementing GLP-1 effects to create a dual drive toward greater caloric deficit and metabolic efficiency.
Self-reported reductions in hunger and prospective food consumption, supporting better adherence and sustained appetite control in trial settings.
Favorable Cardiometabolic and Liver Health Improvements
Reduces waist circumference, systolic/diastolic blood pressure, triglycerides, total cholesterol, LDL, and other lipid markers alongside weight loss.
Lowers liver enzymes (e.g., ALT), liver fat content, and serum uric acid, with benefits for metabolic-associated fatty liver disease and broader cardiometabolic risk profiles.
Supports reductions in inflammatory and hepatic stress indicators, contributing to improved overall metabolic health in populations with obesity-related comorbidities.
Additional Metabolic and Systemic Benefits
Enhances insulin sensitivity, reduces fasting insulin and C-peptide in some contexts, and improves biomarkers of beta-cell function and proinsulin processing.
Shows benefits in special populations, such as BMI and weight reductions in adolescents with obesity, and potential exploratory advantages in neurocognitive or resilience models linked to metabolic improvements.
Maintains efficacy across diabetic and non-diabetic individuals, with greater weight loss magnitude often observed in non-diabetic cohorts or with longer treatment durations.
Synergistic Advantages of Dual GLP-1/Glucagon Agonism
Combines GLP-1-mediated appetite suppression, glucose control, and gastric effects with glucagon-driven increases in energy expenditure, lipolysis, and hepatic fat metabolism for complementary, amplified outcomes.
Often demonstrates superiority over GLP-1 monotherapy (e.g., semaglutide or dulaglutide) in composite glycemic + weight endpoints and total weight reduction, while providing broader coverage of obesity-related metabolic pathways.
Positions as a next-generation option with dose-dependent effects, supporting tailored use for patients needing both robust weight loss and glycemic improvements in clinical development programs.
